同步放化疗治疗中晚期鼻咽癌的疗效观察  

The Observation of Curative Effect of Concurrent Chemoradiotherapy on Patients with Advanced Nasopharyngeal Carcinoma

作　　者：卜祥兆[1] 李向阳[1] 范学梅[1] 

机构地区：[1]徐州市中心医院放疗科,江苏徐州221009

出　　处：《肿瘤基础与临床》2011年第3期220-222,共3页journal of basic and clinical oncology

摘　　要：目的观察同步放化疗治疗52例中晚期鼻咽癌的疗效和毒副反应。方法回顾性分析52例中晚期鼻咽癌患者的临床资料,根据放疗是否联合化疗分为同步放化疗组(26例)和单纯放疗组(26例),同步放化疗组于放疗前、中、后各行PF方案化疗1周期。单纯放疗组只行放疗。结果治疗后3个月后,同步放化疗组和单纯放疗组患者鼻咽原发病灶完全消退率分别为84.6%和61.5%(P<0.05),颈部淋巴结完全消退率分别为80.0%和56.0%(P<0.05),两组1年生存率分别为92.3%和84.6%(P>0.05),两组3年生存率分别为76.9%和46.2%(P<0.05),远处转移率分别为15.4%和42.3%(P<0.05)。早期毒副反应主要为白细胞减少和口腔黏膜炎,均可耐受。结论同步放化疗可以降低远处转移率和提高3年生存率,其毒副反应可以耐受。Objective To evaluate the curative effect of concurrent chemoradiotherapy on the treatment of advanced nasopharyngeal carcinoma.Methods A total of 52 patients with advanced nasopharyngeal carcinoma was divided into the chemoradiotherapy group and the radiotherapy alone group.The chemoradiotherapy group was treated with PF regimen chemotherapy combined with radiotherapy.The radiotherapy alone group was treated with radiotherapy.Results The complete remission rates of nasopharyngeal primary lesions at 3 months after the treatment were 84.6% and 61.5% in the chemoradiotherapy group and the radiotherapy group（P0.05）,and the complete remission rates of neck lymph node were 80.0% and 56.0%（P0.05）,the 1-year survival rates were 92.3% and 84.6%（P0.05）,the 3-year survival rates were 76.9% and 46.2%（P0.05）,the rates of distant metastasis were 15.4% and 42.3%（P0.05）.The early common toxicities were leukopenia and mucosities,and could be tolerated.Conclusion The concurrent chemoradiotherapy can improve the 3-year survival rate and decrease the distant metastasis rate in patients with advanced nasopharyngeal carcinoma,and the toxicities can be tolerated.

关 键 词：鼻咽癌 放化疗 毒副反应 

分 类 号：R739.63[医药卫生—肿瘤] R730.58[医药卫生—临床医学]